Avid Bioservices, Inc. (CDMO) Analysts See $-0.09 EPS

Analysts expect Avid Bioservices, Inc. (NASDAQ:CDMO) to report $-0.09 EPS on December, 10.They anticipate $0.18 EPS change or 66.67 % from last quarter’s $-0.27 EPS. After having $-0.06 EPS previously, Avid Bioservices, Inc.’s analysts see 50.00 % EPS growth. The stock increased 1.73% or $0.09 during the last trading session, reaching $5.3. About 204,353 shares traded. Avid Bioservices, Inc. (NASDAQ:CDMO) has risen 128.25% since December 2, 2017 and is uptrending. It has outperformed by 112.63% the S&P500.

Avid Bioservices, Inc. operates as a contract development and manufacturing organization focusing on the development and cGMP manufacture of biopharmaceutical products derived from mammalian cell culture. The company has market cap of $296.81 million. It provides a range of process development, and cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. It currently has negative earnings. The firm produces monoclonal antibodies and recombinant proteins in batch, fed-batch, and perfusion modes; and provides services, including cGMP clinical and commercial product manufacturing, purification, bulk packaging, stability testing, and regulatory strategy, submission, and support.

More notable recent Avid Bioservices, Inc. (NASDAQ:CDMO) news were published by: Benzinga.com which released: “34 Stocks Moving In Wednesday’s Mid-Day Session – Benzinga” on November 21, 2018, also Nasdaq.com with their article: “Cambrex to Acquire Avista Pharma Solutions, Adding Early Stage API and Finished Dosage Form Development & Testing Services to its Global Contract Development & Manufacturing Network – Nasdaq” published on November 20, 2018, Nasdaq.com published: “Voyager Therapeutics Enters into Strategic Manufacturing Collaborations with Brammer Bio and Fujifilm Diosynth Biotechnologies – Nasdaq” on November 29, 2018. More interesting news about Avid Bioservices, Inc. (NASDAQ:CDMO) were released by: Benzinga.com and their article: “22 Stocks Moving In Monday’s Pre-Market Session – Benzinga” published on September 10, 2018 as well as Nasdaq.com‘s news article titled: “Iovance Biotherapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update – Nasdaq” with publication date: November 06, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.